News | May 19, 2026
Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
The clinical study in France evaluated the safety and feasibility of Robocath’s robotic-assisted coronary intervention platform across complex cardiac cases.
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
